Kornimate/medical-research-clean huggingface dataset:
niclosamide for mild to moderate covid-19

Conditions: COVID-19

Summary: this study will evaluate the antihelmintic drug, niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (covid-19).

niclosamide, which has potent antiviral activity against single-stranded rna viruses including coronaviruses, was proposed as an antiviral during the severe acute respiratory syndrome (sars) outbreak in 2002 and has activity including severe acute respiratory syndrome coronavirus 2 (sars-cov-2) where it was found to inhibit sars coronavirus, sars-cov, in in vitro studies and similarly structured rna viruses (both in vitro and in vivo). the investigators hypothesize that the antiviral activity of niclosamide may be extended to covid-19.

Eligibility criteria:
inclusion criteria: * positive sars-cov-2 test by pcr * no requirement of oxygen supplementation * ability to take oral medication exclusion criteria: * known allergic reactions to any components of niclosamide medication * participation in another trial or use of any experimental treatment for covid-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir * hospitalization or requirement of hospitalization at the time of enrollment

Keywords: sars-cov-2 coronavirus treatment pill telehealth viral shedding
examining the feasibility of wysa in hindi

Conditions: Mental Health Issue; Diabetes Distress

Summary: the principal objective of this study is to investigate the feasibility of including a digital mental health intervention (wysa in hindi) within pre-existing usual care to support adolescents and young adults with type 1 diabetes (t1d) who have mild and above mental health distress (operationalized as patient health questionnaire-9: 5-14 scores; or diabetes distress scale-17: \>2.0 mean score) with their mental health distress. this will be conducted through an exploratory randomized control study comparing wysa in hindi plus usual care with a control arm that just has usual care. the study further explores the effectiveness of the digital mental health intervention using the patient health questionnaire (phq-9) and diabetes distress scale (dds-17).

participants (13-25 years) with type1 diabetes are invited into the study. the intervention being studied is the wysa in hindi app. participants will be recruited from udaan (a non-governmental organization (ngo) supporting individuals with type1 diabetes). they will complete baseline research procedures and be randomly allocated to one of two groups. participants in the intervention arm will get access to the wysa in hindi app as well as access to usual care (individual and group sessions on motivation, mental health, and coping). the control arm will only have access to the usual care i.e. the individual and group sessions. at the end of 2 months, participants will be invited for follow-up to complete the endline assessments.

Eligibility criteria:
inclusion criteria: * age between 13-25 years * diagnosis of type1 diabetes * access to a smartphone with internet connection * can read and understand hindi * mental health distress as demonstrated by elevated scores on any of the scales: mild -moderate symptoms (between 5-14 score) on patient health questionnaire (phq-9), moderate and above diabetes distress (mean score 2.0 and higher) on the diabetes distress scale (dds-17) exclusion criteria: * do not own or have access to a mobile device * are identified to have risk of harm/ suicidality (as identified on phq-9) * are currently undergoing or have received psychiatric support * experience any mental or physical impairments that create accessibility barriers to the use of a smartphone or access to a digital mental health intervention

Keywords: digital mental health
effects of whey and collagen on ffm, muscle strength and wound healing in elderly surgical patients

Conditions: Hip Arthritis; Sarcopenia; Knee Arthritis

Summary: the purpose of the study is to compare the effect of whey protein and collagen on fat free mass, muscle strength, functional ability, wound healing and life quality in elderly patients undergoing elective knee- or hip surgery (defined as elective knee- or hip arthroplasty). the patients are admitted at the department of orthopaedic surgery at herlev gentofte hospital.


Eligibility criteria:
inclusion criteria: * age 65+ years * scheduled elective knee- or hip surgery * must be able to understand and speak danish * must be able to chew and swallow food with a regular consistency * must be able to consume the assigned protein supplementation * must be able to consent participation exclusion criteria: * vegan * demensia * critical complications to the surgery which prevents the patient from participating in the rehabilitation program * plasma-creatinin above 250 micromol/l * palliative patients * known intolerance of whey protein and/or collagen * patients with a pacemaker

Keywords: hip arthroplasty collagen whey protein knee arthroplasty
early tirofiban administration after intravenous thrombolysis in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing ivt

nearly half of acute ischemic stroke patients underwent intravenous thrombolysis (ivt) failed to achieve excellent functional outcome. some studies reported that early administrated tirofiban, a selective glycoproteinⅱb/ⅲa receptor inhibitor, may greatly improve the outcome of patients who received ivt, however they only recruited small sample size. thus, the investigators design early tirofiban administration after intravenous thrombolysis in acute ischemic stroke (advent) trial, aiming to evaluate the efficacy and safety of early tirofiban administration in patients undergoing ivt.

Eligibility criteria:
inclusion criteria: 1. age≥18 years old; 2. clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase ivt within 4.5 hours of onset; 3. total national institute of health stroke scale (nihss)≥4 or single limb motor item score≥2, and total nihss≤15 after ivt; 4. tirofiban or placebo treatment can be initiated within 6h after ivt; 5. mrs score before onset≤ 1; 6. intracranial hemorrhage is ruled out by ct head after ivt; 7. systolic blood pressure before enrollment≤ 160mmhg; exclusion criteria: 1. received or plan to undergo bridge therapy; 2. large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area); 3. atrial fibrillation or suspected cardiac embolism; 4. accompanied by epileptic seizures; 5. using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment; 6. active bleeding or tendency to bleed after receipt of intravenous thrombolysis; 7. digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year; 8. severe renal or liver insufficiency; alt or ast\>3 times of the upper limit of normal value or above; creatinine clearance rate\ 200μmol/l； 9. life expectancy less than 3 months; 10. pregnant or lactating women; 11. known allergy to tirofiban; 12. being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.; 13. patients who are unwilling to be followed up or likely to have poor treatment compliance; 14. other situations that the researcher deems unsuitable for inclusion in the study.

Keywords: acute ischemic stroke intravenous thrombolysis tirofiban
reduction of pre-operative anxiety using a specially designed educational program for breast cancer patients undergoing surgery: a randomized controlled trial

Conditions: Patient Satisfaction; Preoperative Anxiety; Anxiety

Summary: this study aims to find out that if a specially designed educational program can help in reduction of pre-operative anxiety in breast cancer patients undergoing surgery as a part of their treatment.

anxiety can be defined as an unpleasant subjective experience associated with the perception of real threat; therefore, it is a common symptom in connection with cancer. breast cancer patients undergo surgery at some stage of their treatment, surgery details can be overwhelming and might lead to low retention of information and greater levels of anxiety which is the most prevalent psychological symptoms perceived by cancer patients. studies have shown women with a diagnosis of cancer correlate with higher levels of preoperative anxiety. increased anxiety elicits physiologic stress responses that may impede healing and alter responses to postoperative pain.it can also lead to delayed recovery, prolonged hospital stay and increased need of postoperative pain medications. pre-operative anxiety may also cause delayed recovery from anesthesia and can also compromise the effectiveness of anesthesia .furthermore, it can lead to other post-operative complications such as nausea, vomiting, and delayed wound healing. various pharmacological and non-pharmacological methods have been used for reduction of pre-operative anxiety and one such non-pharmacological method is educating the patients about the experience of surgery pre-operatively which we aim to study in our population.

Eligibility criteria:
inclusion criteria: 1. 18 to 70 years of age. 2. known cases of breast cancer. 3. undergoing breast surgery as a part of treatment. 4. availability of personal smart phone at home. 5. written informed consent given for participation in trial. 6. females. exclusion criteria: 1. less than 18 years or more than 70 years of age. 2. stage iv patients undergoing palliative breast surgery. 3. patient having chronic pain. 4. un-availability of smart phone. 5. patients with known psychiatric/depression disorders. 6. previous history of another treated carcinoma. 7. patients with re-current breast carcinoma. 8. male patients are excluded from study.
additional effect of wound infiltration after cesarean section with optimal standard analgesia

Conditions: Postoperative Pain; Anesthesia, Local; Breast Feeding

Summary: the purpose of this study is to determine wether wound infiltration brings additional analgesia effect after cesarean section with optimal standard postoperative analgesia

continuous wound infiltration with local anaesthetic has been shown as a safe and opioid-sparing analgesic method after caesarean section with minimal standard analgesia. we aim to evaluate if this benefit remains when an optimal analgesia is used. primary outcome is morphine consumption. secondary outcomes is pain scores, maternal recovery including breastfeeding, side effects of morphine, nurse workload and maternal satisfaction. patients scheduled for caesarean delivery will be eligible for the study. patients with emergency caesarean delivery, contraindication to analgesic drugs, hemostasis disorder, ongoing infection, diabetes treated with insulin or chronic opioid use will be excluded from the study. one group will receive standard analgesia including celecoxib and intravenous morphine for 24 hours with patient controlled analgesia pump. the other group will receive the same standard analgesia with additional levobupivacaine initial bolus followed by a continuous subfascial infiltration of 1.25 mg/ml at 5 ml/h for 48 hours through a multiperforated catheter connected to an elastomeric pump. total morphine consumption, pain and any associated complications will be recorded for 72 hours. women wil be asked to fulfill a questionnaire on the second day after cesarean section, assessing recovery, satisfaction and breastfeeding comfort.

Eligibility criteria:
inclusion criteria: * scheduled cesarean section exclusion criteria: * emergency cesarean section * contraindication to opioids, paracetamol, or local anaesthetic * ongoing infection * coagulation disorders * diabetes treated with insulin * chronic opioid use

Keywords: postcesarean section postoperative pain care, postoperative anesthesia, local breast feeding morphine pain measurement levobupivacaine
does oral lactate affect gut hormone secretion in a dose-response relationship?

Conditions: Metabolic Syndrome

Summary: to investigate whether there is a linear dose-response relationship between oral lactate and its effects on gut hormone secretion, motility, and appetite. hypothesis oral lactate administration affects gut hormone secretion, insulin levels, motility, appetite sensation and the amount of food intake in a linear dose-response relationship.

the participants will meet up fasting at the steno diabetes centre aarhus research lab. immediately after arrival, they will be placed in a bed. the four trial days will be completely alike, besides the interventions. the participants will have one intravenous (iv.) access placed in the elbow on the four trial days for a continuous drawing of blood samples throughout the trial day. before drinking the intervention, baseline blood samples will be drawn. immediately after drinking the intervention, the participants will take 1500 mg paracetamol to determine ventricular emptying rate through the acetaminophen test. after this, the participants can lay in their bed and watch tv, ipad or work on their computer. blood samples will be collected at 0, 10, 20, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes after the intervention. appetite sensations will be measured by a visual analog scales (vas). after 3 hours the trial day is finished, and the participants can go home. before and after each trial day the participants will collect a fecal sample. we will use anova and mixed model regression analyses for comparing the four groups. based on a previous study we will need 11 individuals to detect a difference of 17,3 pmol/l in mean insulin concentrations at time 60 minutes, with a sd of 18,3 (α=0.05, β=0.80). to account for potential missing values, we will include a total of 12 participants

Eligibility criteria:
inclusion criteria: * 18-75 years * written and oral consent * healthy exclusion criteria: * hba1c \> 39 * taking medicine * any diseases * allergy to paracetamol * doesn't speak or understand danish. * special diets
a study of the c3 inhibitor amy-101 in patients with ards due to covid-19 (save)

Conditions: Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)

Summary: the study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of amy-101, a potent c3 inhibitor, for the management of patients with ards caused by sars-cov-2 infection. we will assess the efficacy and safety, as well as pharmacokinetics (pk), and pharmacodynamics (pd). the study will assess the impact of amy-101 in patients with severe covid19; specifically, it will assess the impact of amy-101 1) on survival without ards and without oxygen requirement at day 21 and 2) on the clinical status of the patients at day 21.


Eligibility criteria:
inclusion criteria: * diagnosed with acute respiratory distress syndrome due to sars-cov-2 infection (severe covid-19), according to the following criteria: 1. demonstration of sars-cov-2 rnaemia in nasopharyngeal swap or bronchio-alveolar lavage (bal) 2. a ratio of the partial pressure of oxygen (pao2) to the fraction of inspired oxygen (fio2), pao2/fio2, ≤300 mmhg * mild ards (pao2/fio2, ≤300 and \>200 mm hg); * moderate ards (pao2/fio2, ≤200 and \>100 mm hg); * severe ards (pao2/fio2, ≤100 mm hg); 3. pulmonary infiltrates suggestive of sars-cov-2-related ards: e.g., bilateral infiltrates at chest x-ray or b-lines at lung us scan. * dated and signed informed consent from patient or legal represantative. exclusion criteria: * intubated patients * demonstrated or suspected uncontrolled systemic severe infection, such as sepsis (e.g.: positive blood culture, or procalcitonin ≥0.25 µg/l) * demonstrated local extrapulmonary abscess * ards due to cardiac failure or fluid overload * concomitant treatment with immunomodulatory /immunosuppressive drugs , which have potential activity against the disease * multi organ failure (mof) * severe renal failure (ckd, by defition glomerular filtration rate \<30 ml/min) * neisseria meningitidis infection that is not resolved * current treatment with a complement inhibitor * intravenous immunoglobulin (ivig) within 3 weeks prior to screening * participation in another interventional treatment study within 30 days before initiation of the study treatment (day 1 in this study) or within 5 half-lives of that investigational product, whichever is greater. * chemotherapy for less than 3months * pregnancy * age \<18.
diagnostic and prognostic value of new quick tests of action slowing in stroke and in cognitive neurodegenerative disease

Conditions: Stroke; Action Speed; Dementia Mild Cognitive Impairment; Alzheimer Disease

Summary: a large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. in stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. in neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. the objectives of this project are to determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (neurovascular unit) and cognitive neurodegenerative disorders (alzheimer disease (ad), lewy body disease (lbd), fronto temporal lobar degeneration (ftld), cortico basal degeneration (cbd) and progressive supra nuclear palsy (psnp)) and to define the lesion determinants with vbm and vlsm


Eligibility criteria:
inclusion criteria: * patients between 40 and 85 years old, * french native language, * social security affiliation. * university memory clinic for: mild severity disorder (mmse\> 19) or major severity disorder related to ad : albert 2011 criteria ; mckhann 2011 * to mcl according to mckeith criteria * to ftld according to rascovsky 2011 criteria * bbd according to armstrong's criteria * related to psp according to höglinger criteria exclusion criteria: * mental retardation or guardianship * previously diagnosed dementia * other current or past brain condition * severe head trauma * epilepsy prior to stroke still requiring previous treatment * parkinson disease, multiple sclerosis... * brain tumor or brain radiation therapy * current or past schizophrenia or psychosis * active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment * contra indication to mri * comorbidity with life expectancy \<1 year * comorbidity affecting cognition in particular: * alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome * opiate or cocaine addiction or opiate withdrawal syndrome * renal failure (dialysis or creatinine clearance \<30) * hepatic failure (spontaneous inr\> 1.5 or pt \<60%) * respiratory failure requiring oxygen therapy * heart failure (orthopnea\> 2 pillows) * persistent vigilance disturbances (nihss1a score ≤1) * cancer with paraneoplastic syndrome * treatment with gold salts, d penicillamine or other treatment with cognitive effect * patient under guardianship or curators or private under public law * pregnant and / or lactating wom

Keywords: executive processes attention stroke action speed diagnostic sensitivity specificity dementia mild cognitive impairment alzheimer disease
a study to evaluate the safety and efficacy of pf-06826647 in participants with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to evaluate efficacy and safety of pf-06826647 in moderate to severe ulcerative colitis


Eligibility criteria:
inclusion criteria: * participants with moderate to severe uc as defined by a total mayo score of ≥6, with a rectal bleeding subscore of ≥1 and an endoscopic subscore of ≥2; * participants must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for uc: oral, intravascular, or intramuscular corticosteroids; immunosuppressants (azathioprine \[aza\], 6-mp, or methotrexate \[mtx\]); anti-tumor necrosis factor (tnf) inhibitors (eg, infliximab, adalimumab, or golimumab); anti-integrin inhibitors (eg, vedolizumab); jak inhibitor (eg, tofacitinib); anti-il-12/il-23 inhibitors (eg, ustekinumab). exclusion criteria: * presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, or crohn's disease * participants displaying clinical signs of fulminant colitis or toxic megacolon; * participants with evidence of colonic dysplasia, adenomas or neoplasia.
the effect of periodontal treatment and the use of dentifrice on glycaemic control in diabetics

Conditions: Periodontal Disease

Summary: to test effectiveness of dentifrice in maintaining periodontal health.


Eligibility criteria:
inclusion criteria: * poor glycaemic control as evidenced by an hba1c of \>6.0% for the past 12 months * aged 18 to 75 years * able to give informed consent * minimum of 12 teeth * chronic periodontitis as indicated by periodontal probing depths \>5mm on at least 6 teeth exclusion criteria: * pregnancy * gross dental caries * prosthetic heart valves, a history of infective endocarditis or any other condition requiring antibiotic cover for dental treatment (rheumatic fever, mitral valve prolapse with regurgitation) * anticoagulant therapy (excluding asprin)
cholesterol goal attainment rate and its associated factors among dyslipidemic patients on lipid-lowering drug therapy in korea

Conditions: Dyslipidemia

Summary: this is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified ncep-atp iii guidelines and define its possible determinants among korean dyslipidemic patients

mc md

Eligibility criteria:
inclusion criteria: * patient who has a dyslipidemia with a lipid profile result within 3 months * patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test. exclusion criteria: * patient who involved in this study previously. * patient who participated in other clinical study with study drug within 90 days.

Keywords: ldl-c, cholesterol, risk factor